These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25809760)

  • 21. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
    Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
    J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New frontiers in the therapy of tuberculosis: fighting with the global menace.
    Chhabria M; Jani M; Patel S
    Mini Rev Med Chem; 2009 Apr; 9(4):401-30. PubMed ID: 19356120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs.
    Sikri K; Duggal P; Kumar C; Batra SD; Vashist A; Bhaskar A; Tripathi K; Sethi T; Singh A; Tyagi JS
    Redox Biol; 2018 May; 15():452-466. PubMed ID: 29413958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model.
    Baijnath S; Moodley C; Ngcobo B; Singh SD; Kruger HG; Arvidsson PI; Naicker T; Pym A; Govender T
    Int J Antimicrob Agents; 2018 Jan; 51(1):77-81. PubMed ID: 28843822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs.
    Sgaragli G; Frosini M
    Curr Med Chem; 2016; 23(12):1186-216. PubMed ID: 27048337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Key targets and relevant inhibitors for the drug discovery of tuberculosis.
    Xiong X; Xu Z; Yang Z; Liu Y; Wang D; Dong M; Parker EJ; Zhu W
    Curr Drug Targets; 2013 Jun; 14(6):676-99. PubMed ID: 23547780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drugs for the treatment of Mycobacterium tuberculosis infection.
    AlMatar M; AlMandeal H; Var I; Kayar B; Köksal F
    Biomed Pharmacother; 2017 Jul; 91():546-558. PubMed ID: 28482292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection caused by Mycobacterium tuberculosis.
    Peloquin CA; Berning SE
    Ann Pharmacother; 1994 Jan; 28(1):72-84. PubMed ID: 8123968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of Tuberculosis.
    Dobbs TE; Webb RM
    Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28387179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.
    Tanner L; Denti P; Wiesner L; Warner DF
    IUBMB Life; 2018 Sep; 70(9):926-937. PubMed ID: 29934964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models in tuberculosis research - where is the beef?
    Myllymäki H; Niskanen M; Oksanen KE; Rämet M
    Expert Opin Drug Discov; 2015; 10(8):871-83. PubMed ID: 26073097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.
    Grotz E; Tateosian N; Amiano N; Cagel M; Bernabeu E; Chiappetta DA; Moretton MA
    Pharm Res; 2018 Sep; 35(11):213. PubMed ID: 30238168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From the past, a long way to future challenges for a greater control of tuberculosis.
    Villa S; Riccardi N; Canetti D; Alagna R; Castellotti P; Ferrarese M; Cirillo D; Barberis I; Bragazzi NL; Gazzaniga V; Ricucci V; Codecasa LR; Besozzi G; Martini M
    Tuberculosis (Edinb); 2020 Jul; 123():101948. PubMed ID: 32741532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.